Adult T-cell Leukemia/Lymphoma (ATLL)
What is Adult T-cell Leukemia/Lymphoma (ATLL)?
Adult T-cell leukemia/lymphoma is a rare and aggressive type of blood cancer. It affects white blood cells called T-cells, which normally help your immune system fight infections. This cancer is caused by infection with a virus called human T-cell lymphotropic virus type I, or HTLV-I.
HTLV-I spreads through breastfeeding, sexual contact, blood transfusions, and sharing needles. Most people who carry this virus never develop cancer. Only about 2 to 5 out of every 100 people infected with HTLV-I will develop ATLL during their lifetime. The cancer usually appears decades after the initial infection, often in people over age 40.
ATLL is most common in southwestern Japan, the Caribbean, parts of Africa, and South America. In the United States, it remains quite rare. When ATLL does develop, it can affect the blood, lymph nodes, skin, and other organs. The disease ranges from slow-growing forms to very aggressive types that require urgent treatment.
Symptoms
- Swollen lymph nodes in the neck, armpits, or groin
- Skin rashes, lumps, or patches that may be itchy
- Fatigue and weakness that does not improve with rest
- Unexplained weight loss over a few months
- Frequent infections due to weakened immunity
- Bone pain or fractures from calcium imbalances
- Abdominal swelling or pain from enlarged organs
- Fever without an obvious infection
- Night sweats that soak through clothing
- Cough or difficulty breathing if lungs are affected
Some people with slow-growing forms may have few or no symptoms early on. Others experience rapid symptom onset when the disease is aggressive.
Concerned about Adult T-cell Leukemia/Lymphoma (ATLL)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
ATLL is caused by infection with the HTLV-I virus. This virus changes the DNA inside T-cells over many years, eventually causing some cells to become cancerous. The virus spreads from mother to child through breastfeeding, between sexual partners, through contaminated blood products, or by sharing needles. You cannot get HTLV-I through casual contact like hugging or sharing food.
Risk factors include being born in areas where HTLV-I is common, having a mother infected with the virus, receiving blood transfusions before screening began, and sharing needles for drug use. People who carry HTLV-I for 40 to 60 years have the highest risk of developing ATLL. Genetic factors may also play a role in who develops cancer after infection, but researchers are still studying these connections.
How it's diagnosed
Doctors diagnose ATLL through blood tests, imaging scans, and tissue samples. Blood work checks for abnormal T-cells with distinctive flower-shaped nuclei and elevated calcium levels. Testing for HTLV-I antibodies confirms viral infection. A complete blood count shows how many white blood cells, red blood cells, and platelets are present.
Additional tests include bone marrow biopsies, lymph node biopsies, and imaging studies like CT scans or PET scans. These help determine how far the cancer has spread. Rite Aid offers HTLV I/II antibody testing, which can detect exposure to the virus. Talk to a doctor about specialized testing if you have symptoms or known HTLV-I infection. Early detection of the virus helps doctors monitor you over time.
Treatment options
- Chemotherapy using multiple drugs to kill cancer cells
- Antiviral medications combined with interferon for some subtypes
- Stem cell transplant for eligible patients with aggressive disease
- Targeted therapy drugs that attack specific cancer cell proteins
- Radiation therapy for localized tumors or skin lesions
- Medications to manage high calcium levels in the blood
- Supportive care including antibiotics to prevent infections
- Clinical trials testing new treatment approaches
- Watchful waiting for very slow-growing forms without symptoms
Treatment depends on the ATLL subtype, how far it has spread, and your overall health. Aggressive forms require urgent chemotherapy. Slower forms may only need monitoring at first. Work closely with a cancer specialist experienced in treating this rare disease.
Frequently asked questions
ATLL is unique because it is caused by a specific virus, HTLV-I, rather than genetic mutations alone. It affects T-cells specifically, while many leukemias affect B-cells or other blood cell types. ATLL tends to be more aggressive than many other lymphomas and is much rarer in Western countries. Treatment approaches differ because the viral cause influences how the cancer behaves.
A blood test for HTLV-I antibodies can show if you have ever been infected with the virus. Most people with HTLV-I have no symptoms and will never develop cancer. Testing is recommended if you were born in high-risk areas, have a parent with HTLV-I, received blood transfusions before 1988, or have unexplained neurological symptoms. Talk to your doctor about whether testing makes sense for you.
Some forms of ATLL can be cured, especially slower-growing types treated early. Aggressive forms are harder to cure but may respond well to intensive chemotherapy followed by stem cell transplant. Response rates vary widely based on the specific subtype and how far the disease has spread. Even when cure is not possible, treatment can extend life and improve quality of life significantly.
The four subtypes are acute, lymphoma, chronic, and smoldering. Acute and lymphoma types are aggressive and require immediate treatment. Chronic and smoldering types grow more slowly and may only need monitoring at first. Your subtype affects your prognosis and treatment plan. Doctors determine your subtype based on blood counts, organ involvement, and calcium levels.
ATLL itself is not contagious, but the virus that causes it can spread to others. HTLV-I spreads through breastfeeding, sexual contact, blood exposure, and shared needles. If you have HTLV-I, you should not breastfeed, donate blood, or share needles. Use protection during sexual activity to reduce transmission risk. Casual contact does not spread the virus.
Survival depends heavily on the subtype and response to treatment. Aggressive acute and lymphoma types have median survival of 6 to 10 months without treatment, but some patients live much longer with intensive therapy. Chronic and smoldering types can have survival measured in years, sometimes decades. Stem cell transplant offers the best chance for long-term survival in eligible patients.
ATLL cells release substances that tell your bones to break down and release calcium into the bloodstream. This condition, called hypercalcemia, affects about half of people with aggressive ATLL. High calcium can cause confusion, extreme thirst, frequent urination, and kidney problems. Treating the cancer usually brings calcium levels back to normal. Medications and IV fluids can also help manage calcium quickly.
Yes, close family members should consider testing, especially if the patient's mother is still living or if there are children. Mothers can pass HTLV-I to babies through breastfeeding. Sexual partners should also be tested. Knowing your status helps you make informed decisions about breastfeeding, blood donation, and monitoring. Remember that most people with HTLV-I never develop cancer.
No specific lifestyle changes have been proven to prevent ATLL in HTLV-I carriers. Maintaining overall good health through balanced nutrition, regular exercise, and avoiding tobacco may support your immune system. Regular medical monitoring is the most important step if you carry the virus. This allows doctors to detect early changes in blood counts or lymph nodes before symptoms appear.
First, talk to a doctor who understands HTLV-I to confirm the result and discuss what it means. You will need regular monitoring with blood work and physical exams, usually once or twice a year. Take steps to prevent spreading the virus to others. Most importantly, remember that only a small percentage of carriers ever develop ATLL. Many people with HTLV-I live normal, healthy lives with appropriate precautions and monitoring.